# Pimavanserin and Aggression and Social Cognition.

> **NCT05895513** · PHASE2 · RECRUITING · sponsor: **Ohio State University** · enrollment: 35 (estimated)

## Conditions studied

- Intermittent Explosive Disorder

## Interventions

- **DRUG:** Pimavanserin 34 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05895513
- **Lead sponsor:** Ohio State University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2027-01
- **Final completion:** 2028-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05895513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05895513, "Pimavanserin and Aggression and Social Cognition.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05895513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*